Search Results
Jun 16, 2026, 09:00 ET Ivim Health launches HormoneIQ™, treating a woman's hormone symptoms as clinical data
HRT formulary," said HypoSpray Pharma Chairman Kenneth B. Kirby.Physician-prescribed protocols include estradiol, progesterone, DHEA, GLP-1 therapy, sexual health medications, longevity protocols, and combination therapies, delivered alongside lifestyle education with functional health
More news about: Ivim Health
Jun 16, 2026, 09:00 ET Catalina Snacks Launches New Snack Size Multipacks Ahead of National "Snack Like It Matters™" Campaign
crunch, helping keep consumers full and satisfied for whatever the day brings. With many consumers following high-protein eating habits and GLP-1-related nutrition plans, Catalina Crunch continues to focus on delivering satisfying snacks with meaningful nutrition.The new Snack Size Multipacks
More news about: Catalina Crunch
Jun 16, 2026, 08:15 ET Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
advanced wound care, periodontal applications, and facial and body contouring (including the soft-tissue laxity associated with rapid GLP-1-driven weight loss), with longer-term expansion into 3D printing and biofabrication and even veterinary medicine. Conexeu has also unveiled a 3D-bioprinted
More news about: American News Group
Jun 15, 2026, 11:18 ET LYMA LAUNCHES THE FORMULA THE LONGEVITY WORLD DIDN'T KNOW IT WAS MISSING
entirely their own. Not a single moment of transformation, but a system working as it should.FOR GLP-1 USERS: THE FORMULA BUILT FOR YOUR PROTOCOLAs GLP-1 medications reshape the global conversation about weight and metabolic health, LYMA ID² addresses the nutritional
More news about: LYMA
Jun 15, 2026, 11:00 ET From TikTok Viral to Whole Foods Shelf in 18 Months -- Down from Four-to-Six Years: 5W Releases the F&B Retail Acceleration Playbook 2026
months."The playbook also documents the GLP-1 reset: declining volume in alcohol, sugary beverages, and indulgent snacks; rising volume in high-protein, functional, and portion-controlled formats. Legacy F&B brands treating GLP-1 as a temporary headwind are conceding permanent
More news about: 5W Public Relations
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
homeostatic model assessment for insulin resistance (HOMA‑IR) at Months 12 and 24. To avoid potential confounding from glucagon-like peptide-1 (GLP-1) receptor agonists and/or glucose-dependent insulinotropic polypeptide (GIP) use, data from participants taking these medications (n=9) were
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 06:00 ET Weight-Loss Drugs Are Reshaping the Body. New Yorkers Are Rethinking What Comes Next
2026 /PRNewswire/ -- Something unexpected is happening in aesthetic clinics across New York. Clients who have lost significant weight through GLP-1 medications like Ozempic and Wegovy are arriving with a new set of concerns, and hair removal is quietly becoming part of that conversation. As
More news about: Laser by Aleya
Jun 12, 2026, 08:53 ET In HelloNation, Medical Weight Loss Expert Patty Schultz Explains Semaglutide and Tirzepatide
and sustainable lifestyle changes to be truly successful.Schultz explains that semaglutide belongs to a class of medications known as GLP-1 receptor agonists. These drugs mimic a natural hormone, glucagon-like peptide-1, which is released in the gut after eating and sends signals to
More news about: HelloNation
Jun 12, 2026, 08:00 ET Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
bofanglutide injection was generally well tolerated in both the 24 mg and 48 mg groups. The safety profile was consistent with that of other GLP-1 RAs. The most common adverse events were gastrointestinal reactions and were mostly mild to moderate and transient, with no new safety signals identified.
More news about: Gan & Lee Pharmaceuticals
Jun 12, 2026, 05:55 ET UK's leading longevity clinic Get A Drip appoints new Chief Medical Officer Dr Luke Pratsides
experience in both the private sector and frontline NHS practice. Dr Pratsides formerly led the medical team at Numan where he built the company's GLP-1 and testosterone hormone therapy prescribing services and clinical governance structures."We are delighted to welcome Dr Luke Pratsides as
More news about: Get A Drip
Jun 12, 2026, 00:52 ET ウォーターズ、業界初となる逆相バイオセパレーションカラムを発売 -- GLP-1 特性解析を最大 3 倍、LNP 成分分析を最大 2 倍高速化
部門において、消耗品およびラボオートメーション担当バイスプレジデント兼ゼネラルマネージャーを務める Erin Chambers は、次のように述べています。「ウォーターズは、化学技術と充てん剤設計の両面での革新を実現することによって、GLP–1 分析4および脂質ナノ粒子分析2向けに QC バッチ試験を実施した専用カラムとしては初めてとなる製品を市場に投入し、お客様が長年抱えてきた課題の解決に貢献してきました。BioResolve Peptide カラムおよび GTxResolve Lipid カラムは、迅速な分析が求められる場面では GLP–1 の類似不純物やLNP成分をより短時間で分離し2,3
More news about: Waters Corporation
Jun 11, 2026, 08:44 ET Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. "GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling
More news about: Pacific Research Institute
Jun 11, 2026, 08:28 ET AEROFARMS ACQUIRED BY AN AFFILIATE OF PALM VENTURES, POSITIONS U.S. MICROGREENS LEADER FOR EXPANDED DISTRIBUTION AND LONG-TERM GROWTH
foods that have the potential to offer functional nutrition to support lifestyles and weight management, accelerated by increasing use of GLP-1 medications among consumers."AeroFarms is exactly the kind of mission-driven company we bring our intellectual, relational, and financial
More news about: New AeroFarms Inc
Jun 11, 2026, 07:05 ET Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Dr. Chen led obesity and type 2 diabetes programs at Amylin Pharmaceuticals, including combinatorial approaches using glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and amylin analogs."Joining the Viking team at this exciting time of growth is an
More news about: Viking Therapeutics, Inc.
Jun 11, 2026, 00:54 ET Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were delivered
More news about: Caliway Biopharmaceuticals
Jun 10, 2026, 16:56 ET Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031
models.Frost & Sullivan notes that growth opportunities are increasingly concentrated around biologics and next-generation modalities, including GLP-1 therapies, antibody-drug conjugates (ADCs), radioligand therapies, and cell and gene therapies, while surrounding ecosystems such as obesity care
More news about: Frost & Sullivan
Jun 10, 2026, 16:56 ET Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031
models.Frost & Sullivan notes that growth opportunities are increasingly concentrated around biologics and next-generation modalities, including GLP-1 therapies, antibody-drug conjugates (ADCs), radioligand therapies, and cell and gene therapies, while surrounding ecosystems such as obesity care operating
More news about: Frost & Sullivan
Jun 10, 2026, 13:13 ET The GLP-1 Era: How To Lose Weight Without Losing Muscle
support, GLP-1 user loses 70+ pounds of body fat while preserving vital lean muscleFITCHBURG, Mass., June 10, 2026 /PRNewswire/ -- Millions of Americans are turning to GLP-1 medications such
More news about: Nutrishop
Jun 10, 2026, 12:22 ET Program Announcement for Annual ASPC Congress on CVD Prevention, July 2026
@AnnMarieNavar vs. Ann Marie Navar, MDUpper Limits of "Healthy" Exercise — Budoff vs. FranklinGLP-1s Should Be Prescribed Widely — Lincoff vs. MozaffarianHigh CAC Scores and Additional Imaging — Villines vs. Gulati2026
More news about: The American Society for Preventive Cardiology
Jun 10, 2026, 10:15 ET Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker
medicine, cardiology, and primary care to test tens of thousands of patients.As treatment options for sleep apnea diversify, including GLP-1 therapies that jointly influence sleep, metabolic, and cardiovascular health, demand for home sleep apnea testing from upstream cardiology and primary
More news about: Huxley Medical, Inc.
Jun 10, 2026, 09:30 ET Benefits Costs Now Employers' No. 1 Concern, Espresa's Benchmark Report Reveals
and prescription costs. Meanwhile, one in four say GLP-1 access directly affects how they perceive their employer's benefits. Employer GLP-1 spend doubled in a single year, from $11 to $24 per member per month, and GLP-1s now represent 10.5% of all prescription drug claims, up
More news about: Espresa
Jun 10, 2026, 09:30 ET Zepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
injection Zepbound® (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how
More news about: Eli Lilly and Company
Jun 10, 2026, 09:00 ET California Milk Advisory Board Opens Applications for 2026 Real California Milk Excelerator With a Focus on Commercialization, Retail Growth and AI-Enabled Scaling
As consumer demand for high-protein foods, functional nutrition, gut health products, clean-label ingredients and GLP-1-compatible eating patterns continue, dairy's nutritional advantages are creating significant opportunities for value-added dairy-based innovation.Applications
More news about: Real California Milk
Jun 10, 2026, 08:00 ET Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
Meeting Presentation Details:Oral PresentationTitle: Concomitant Aroxybutynin and Atomoxetine (AD109) with GLP-1 Agonists: An Analysis of the SynAIRgy and LunAIRo Trials in Obstructive Sleep ApneaSession: O-23 – Frontiers in Sleep Medicine:
More news about: Apnimed, Inc.
Jun 10, 2026, 01:08 ET 康霈於美國糖尿病協會 ADA 2026 首度公開 CBL-514 併用「瘦瘦針」最新動物數據OI25, 展現「減緩復胖、改善代謝」雙重潛力
國際權威加持 — 康霈局部減脂新藥 CBL-514 併用 GLP-1/RA 類藥物之最新動物實驗數據，於美國糖尿病協會年會（ADA 2026）完成發表，並由全球肥胖與代謝醫學領袖、康霈科學顧問 Timothy Garvey 醫學博士（MD）親自擔綱講者，引發國際大廠高度關注。突破復胖痛點 — 首度公開之 OI25 動物實驗數據證實：CBL-514 聯用 GLP-1/RA，相較單藥治療能顯著降低更多體重；停藥後，單用組之體重回升幅度高達併用組的 2.7 倍，驗證聯用療法具備「預防復胖」的強大潛力。多重代謝指標改善 — 數據指出，CBL-514
More news about: 康霈生技